FDA Approval Summary: Nadofaragene Firadenovec-vncg for Bacillus Calmette–Guérin–Unresponsive Non–Muscle-Invasive Bladder Cancer - Colbert, Laronna; Jia, Yuxia; Sharma, Anurag; Hu, Jiang; Xu, Zhenzhen; Suzman, Daniel L.; Das, Asha; Bross, Peter; Kluetz, Paul G.; Fashoyin-Aje, Lola A. (Clinical cancer research, 2025)
Keywords: Adenoviridae - genetics; Administration, Intravesical; Adult; Aged; Aged, 80 and over; BCG Vaccine - therapeutic use; Carcinoma in Situ - pathology; Carcinoma in Situ - therapy; Female; Genetic Therapy - methods; Genetic Vectors - administration & dosage; Genetic Vectors - genetics; Humans; Male; Middle Aged; Mycobacterium bovis; Non-Muscle Invasive Bladder Neoplasms; Treatment Outcome; United States; United States Food and Drug Administration; Urinary Bladder Neoplasms - genetics; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - therapy; United States